All articles tagged with #hormone therapy
Rising demand for menopause hormone therapy—accelerated by FDA label changes and greater public awareness—is outpacing the supply of estrogen transdermal patches, leading to intermittent stockouts, patient brand-switching, and higher costs. Doctors are advising alternatives (other patches, gels, pills) and working with manufacturers to increase capacity as supply catches up.
A WHO-commissioned meta-analysis of data on more than a million women finds no strong evidence that menopause hormone therapy (MHT/HRT) increases or decreases dementia risk. Most studies are observational with inconsistent, low-certainty results; one randomized trial suggested a possible risk with estrogen-only MHT after age 65, but certainty is low. The findings align with the 2024 Lancet Commission and FDA reassessment, and researchers call for more high-quality studies—especially in premature menopause—to clarify MHT’s role in cognitive health.
Recent research has challenged the long-held belief that testosterone promotes prostate cancer growth, showing that testosterone therapy is safe for men with low levels and may even help in managing prostate cancer, leading to a shift in medical practice and treatment approaches.
The article discusses the historical decline and recent resurgence of testosterone therapy in medicine, highlighting how misconceptions, particularly linking testosterone to prostate cancer, led to its decline. Abraham Morgentaler played a key role in challenging these beliefs through clinical evidence, showing that testosterone therapy is safe for men with hypogonadism and emphasizing the importance of considering individual patient experiences. The piece also explores the cultural and medical biases that have hindered the acceptance of testosterone treatment.
Hormone therapy for menopause, recently freed from outdated FDA warnings, can significantly improve skin health by increasing collagen, hydration, and barrier function, while also managing menopausal symptoms; proper treatment choices and skincare routines can optimize benefits and minimize side effects.
US health leaders are advocating for the removal of the black box warning on hormone therapy for menopause, citing new evidence of its benefits and calling for balanced, individualized treatment discussions, though some experts warn of potential risks and the need for nuanced understanding.
The FDA plans to remove safety warnings from hormone replacement therapy products used for menopause, sparking debate about balancing risks and benefits, with experts emphasizing the need for informed, personalized decision-making.
Science and medical guidelines have evolved, leading to a more nuanced view of hormone therapy for menopause. Starting therapy before age 60 or within ten years of menopause can provide relief from symptoms like hot flashes and night sweats, and offer benefits for bone and heart health. However, not all women are suitable candidates, and risks vary depending on the type of estrogen used and individual health conditions. Alternatives like non-hormonal medications and lifestyle changes are also available for managing menopausal symptoms.
The FDA plans to remove black box warnings on menopause hormone therapy, potentially increasing access for women to this treatment.
The FDA has decided to remove the black box warning on hormone replacement therapy for menopause, citing new evidence of its benefits and nuanced risks, which could lead to increased use among women experiencing menopause symptoms.
The FDA has removed the 'black box' warning on hormone replacement therapy for menopause, citing new research that shows the treatments are safer than previously thought, which may increase their use among women and doctors. The agency will still warn about endometrial cancer risk and has approved two new menopause-related drugs. This change follows a reevaluation of past studies linking hormone therapy to serious health risks, and reflects a broader shift in conversations about women's health during midlife.
The FDA announced it will remove the bold warning label on over 20 hormone-based menopause drugs about risks like stroke and heart attack, citing recent studies suggesting these drugs are safer when used before age 60 or within 10 years of menopause, and supporting a more nuanced understanding of their benefits and risks.
The FDA is removing the black box safety warnings on hormone therapy products for menopause, citing a more nuanced understanding of their benefits and risks, and emphasizing the potential health benefits of these therapies when prescribed appropriately. The decision follows public comments and studies suggesting hormone therapy can reduce risks of Alzheimer's, heart attack, and fractures, despite past concerns about cancer and stroke risks.
The FDA plans to remove the black box warning from many hormone treatments for menopause, a move expected to increase access and prescriptions for hormone therapy, which has been underused due to fears of health risks. Experts argue that the warning has unnecessarily scared women away from beneficial treatments, and recent data suggest that hormone therapy is safer for women under 60 or within 10 years of menopause, potentially improving quality of life and health outcomes.
The FDA plans to remove the 'black box' warning labels from many menopause hormone therapy drugs, acknowledging that previous fears based on flawed research led to millions of women being denied beneficial treatment, which could improve heart health, cognitive function, and bone density. FDA Commissioner Dr. Marty Makary called the demonization of hormone therapy an 'American tragedy' and emphasized the importance of updated, nuanced understanding and patient-doctor discussions.